病毒学抑制的HIV-1感染者简化至阿扎那韦/利托那韦联合拉米夫定后全身炎症标志物:ATLAS-M亚研究
ATLAS-M随机试验亚研究纳入139例病毒学抑制的HIV-1感染者,比较简化至阿扎那韦/利托那韦联合拉米夫定双药治疗与继续标准三药治疗对全身炎症标志物的影响。48周时两组IL-6、CRP、sCD14和D-二聚体自基线变化无显著差异。作者认为简化治疗不影响血浆全身炎症标志物,其与临床结局的关联需进一步评估。
要点
- 简化至阿扎那韦/利托那韦联合拉米夫定双药治疗48周不显著改变IL-6、CRP、sCD14和D-二聚体水平。
- 双药组与三药组各项炎症标志物自基线至48周的变化均无显著差异。
- 癌症病史与较高的基线IL-6(P=0.002)和CRP(P=0.049)水平相关。
核心结论
- 简化至阿扎那韦/利托那韦联合拉米夫定不影响病毒学抑制患者的血浆全身炎症标志物。
- 这些发现与临床结局的关联需进一步评估。
研究设计与样本
- 随机对照ATLAS-M试验的亚研究,比较简化至阿扎那韦/利托那韦联合拉米夫定双药治疗与继续阿扎那韦/利托那韦联合两种核苷类逆转录酶抑制剂三药治疗对全身炎症标志物的影响。
- 266例随机患者中139例有可用样本被分析:三药治疗组69例,双药治疗组70例。
- 采用ELISA法在基线及48周定量血浆白细胞介素-6、C反应蛋白、可溶性CD14和D-二聚体水平。
主要发现
- 基线炎症标志物水平在随机分组间相当。
- 双药组 vs 三药组自基线至48周的变化:IL-6为-0.030 vs -0.016 log10 pg/L;CRP为+0.022 vs +0.027 log10 pg/mL;sCD14为-0.016 vs +0.019 log10 pg/mL;D-二聚体为-0.031 vs +0.004 log10 pg/mL,组间均无显著差异。
- 癌症病史与较高的基线IL-6水平(P=0.002)和CRP水平(P=0.049)相关。
- 基线生物标志物水平与持续性残余病毒血症、HIV-1 DNA载量、血浆脂质及其他潜在解释变量之间未观察到关系。
局限性
- 这些发现与临床结局的关联需进一步评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Biomarkers of systemic inflammation predict non-AIDS events and overall mortality in virologically suppressed HIV-1-infected patients. OBJECTIVES: To determine whether switching to a dual antiretroviral maintenance therapy was associated with modification of biomarkers of systemic inflammation as compared with continuation of successful standard triple therapy. METHODS: In this substudy of the randomized ATLAS-M trial, we compared in virologically suppressed patients the impact at 1 year of simplification to a dual therapy with atazanavir/ritonavir plus lamivudine versus maintaining atazanavir/ritonavir plus two NRTI triple therapy on markers of systemic inflammation. Plasma levels of interleukin-6, C-reactive protein (CRP), soluble CD14 (sCD14) and D-dimer were quantified by ELISA at baseline and at 48 weeks. RESULTS: A subset of 139 of 266 randomized patients with available samples was analysed: 69 in the triple therapy arm and 70 in the dual therapy arm. The baseline biomarker levels were comparable between randomization arms. No significant differences in changes from baseline to week 48 were observed between arms (dual therapy versus triple therapy): IL-6, -0.030 versus -0.016 log10 pg/L; CRP, +0.022 versus +0.027 log10 pg/mL; sCD14, -0.016 versus +0.019 log10 pg/mL; and D-dimer, -0.031 versus +0.004 log10 pg/mL. A history of cancer was associated with higher baseline levels of IL-6 (P = 0.002) and CRP (P = 0.049). No relationship was observed between baseline biomarker level and persistent residual viraemia, HIV-1 DNA load, plasma lipids and other potential explanatory variables. CONCLUSIONS: Simplification with atazanavir/ritonavir plus lamivudine does not affect plasma markers of systemic inflammation in virologically suppressed patients. The association between these findings and clinical outcomes requires further evaluation.
引用
- Belmonti S, Lombardi F, Quiros-Roldan E, et al. Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. J Antimicrob Chemother. 2018. PMID: 29788156. doi:10.1093/jac/dky125
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。